AlphaFold predicted structure
MCM7 · P33993
Mean pLDDT
80.4/ 100
Confident
719 residues
Confidence breakdown
- Very high(≥ 90)12%
- Confident(70–90)74%
- Low(50–70)11%
- Very low(< 50)3%
Open interactive 3D viewer
AlphaFold (Jumper et al., 2021) · CC BY 4.0
MCM7
Chr 7q22.1minichromosome maintenance complex component 7
- Aliases:
- CDC47, PPP1R104
- MANE:
- ENST00000303887.10
Annotations refreshed 9 hours ago.
Predicted protein structure
Clinical relevance (Genomics England PanelApp)
Moderate Evidence (Amber)
Severe microcephaly
BIALLELIC, autosomal or pseudoautosomal
Disease associations (Open Targets)
Spastic paraplegia
0.53Meier-Gorlin syndrome
0.53Severe intellectual disability and progressive spastic paraplegia
0.53microcephaly
0.47Trichiasis
0.43microphthalmia
0.43Anisometropia
0.43Deeply set eye
0.43Astigmatism
0.43Progeroid facial appearance
0.43
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Protein function (UniProt)
DNA replication licensing factor MCM7
Acts as a component of the MCM2-7 complex (MCM complex) which is the replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. Core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built (PubMed:25661590, PubMed:32453425, PubMed:34694004, PubMed:34700328, PubMed:35585232, PubMed:9305914). The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity (PubMed:32453425). Required for S-phase checkpoint activation upon UV-induced damage